drugset / Trial / NCT00858962
Buprenorphine/Raltegravir Pharmacokinetic Interaction Study
Completed
12 enrolled
Yale University
Merck Sharp & Dohme LLC · collabNational Institute on Drug Abuse (NIDA) · collab
NaSingle-groupOpen-labelTreatment
Summary
The main purpose of this protocol is to study the effect of an HIV medication known as Raltegravir on Buprenorphine in people who have been receiving the same dose of Buprenorphine for at least 3 weeks before study entry. This will be determined by giving Raltegravir along with Buprenorphine and by measuring the amount of Raltegravir and Buprenorphine in the blood. The investigators will also learn about the effects of Buprenorphine on Raltegravir and about the safety of taking these two medications together.
Timeline
- Start
- 2009-03
- Primary completion
- 2009-12
- Completion
- 2009-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Raltegravir | Other / unclassified | 400 mg | Oral |